NCT01193101 - Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension | Biotech Hunter

Enrollment

389

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Hypertension

Interventions

DRUG

LCZ696

DRUG

Placebo

matching placebo to LCZ696

Trial Locations (34)

114

Novartis Investigative Site, Taipei

500

Novartis Investigative Site, Changhua

10002

Novartis Investigative Site, Taipei

10400

Novartis Investigative Site, Bangkok

10449

Novartis Investigative Site, Taipei

10700

Novartis Investigative Site, Bangkok

40447

Novartis Investigative Site, Taichung

50200

Novartis Investigative Site, Chiang Mai

100044

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

300142

Novartis Investigative Site, Tianjin

310009

Novartis Investigative Site, Hangzhou

400042

Novartis Investigative Site, Chongqing

050000

Novartis Investigative Site, Shijiazhuang

231-0023

Novartis Investigative Site, Yokohama

329-0498

Novartis Investigative Site, Shimotsuke

113-0031

Novartis Investigative Site, Bunkyo-ku

113-8655

Novartis Investigative Site, Bunkyo-ku

100-0005

Novartis Investigative Site, Chiyoda-ku

204-0021

Novartis Investigative Site, Kiyose

186-0001

Novartis Investigative Site, Kunitachi

105-7390

Novartis Investigative Site, Minato-ku

108-0075

Novartis Investigative Site, Minato-ku

143-0023

Novartis Investigative Site, Ōta-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

142-0053

Novartis Investigative Site, Shinagawa-ku

142-0063

Novartis Investigative Site, Shinagawa-ku

171-0021

Novartis Investigative Site, Toshima-ku

424-717

Novartis Investigative Site, Bucheon-si

137-701

Novartis Investigative Site, Seoul

410-719

Novartis Investigative Site, Koyang

705-703

Novartis Investigative Site, Daegu

150-950

Novartis Investigative Site, Seoul

152-703

Novartis Investigative Site, Seoul